any one of claims **1** to **18** in the presence of tumor cell-derived material (TCDM), to produce TAA presentation inducer construct-activated ISR-expressing cells, and

c) determining the sequence of TAA peptides eluted from MHC complexes of the TAA presentation inducer construct-activated ISR-expressing cells; and

d) identifying the TAAs corresponding to the TAA peptides.

32. A method of identifying T cell receptor (TCR) target polypeptides, comprising

a) isolating T cells and enriched innate stimulatory receptor (ISR)-expressing cells from a subject;

b) culturing the ISR-expressing cells and the T cells with the TAA presentation inducer construct according to any one of claims **1** to **18** in the presence of tumor cell-derived material (TCDM), to produce TAA presentation inducer construct-activated ISR-expressing cells and activated T cells, and

c) screening the activated T cells against a library of candidate TAAs to identify the TCR target polypeptides.

33. Use of a therapeutically effective amount of the tumor-associated antigen (TAA) presentation inducer construct according to any one of claims **1** to **18** in the treatment of a cancer in a subject in need thereof.

34. Use of the tumor-associated antigen (TAA) presentation inducer construct according to any one of claims **1** to **18** in the preparation of a medicament for the treatment of a cancer in a subject in need thereof.

35. Use of a therapeutically effective amount of the TAA presentation inducer construct according to any one of claims **1** to **18** for induction of major histocompatibility complex (MEW) presentation of peptides from two or more tumor-associated antigens (TAAs) by a single innate stimulatory receptor-expressing cell simultaneously, in a subject in need thereof.

36. Use of the TAA presentation inducer construct according to any one of claims **1** to **18** in the preparation of a medicament for induction of major histocompatibility complex (MHC) presentation of peptides from two or more tumor-associated antigens (TAAs) by a single innate stimulatory receptor-expressing cell simultaneously, in a subject in need thereof.

37. Use of a therapeutically effective amount of the tumor-associated antigen (TAA) presentation inducer construct according to any one of claims **1** to **18** for induction of innate stimulatory receptor-expressing cell activation in a subject in need thereof.

38. Use of the tumor-associated antigen (TAA) presentation inducer construct according to any one of claims **1** to **18** in the preparation of a medicament for induction of innate stimulatory receptor-expressing cell activation in a subject in need thereof.

39. Use of a therapeutically effective amount of the tumor-associated antigen (TAA) presentation inducer construct according to any one of claims **1** to **18** for induction of a polyclonal T cell response in a subject in need thereof.

40. Use of the tumor-associated antigen (TAA) presentation inducer construct according to any one of claims **1** to **18** in the preparation of a medicament for induction of a polyclonal T cell response in a subject in need thereof.

41. Use of a therapeutically effective amount of expanded, activated or differentiated T cells prepared according to the method of claim **28** or **29** in the treatment of a cancer in a subject in need thereof.

42. Use of expanded, activated or differentiated T cells prepared according to the method of claim **28** or **29** in the preparation of a medicament for treating cancer in a subject in need thereof.

* * * * *